Sales of Lilly’s top-selling product, the diabetes treatment Mounjaro, jumped 60% to $3.53 billion in the final quarter of 2024 while its obesity treatment counterpart Zepbound brought in $1.9 billion.
Diabetes and obesity drugs fuel Eli Lilly profit in the final quarter of 2024 Eli Lilly’s profit doubled in the fourth quarter, propelled by its hot-selling diabetes and obesity treatments, and the drugmaker came out with a mostly better-than-expected 2025 forecast.
Analysts expect more than $18 billion in sales from Mounjaro this year and over $10 billion from Zepbound, which was recently approved in the United States as a treatment for some forms of sleep apnea.
For 2024, Mounjaro sales more than doubled to $11.54 billion, while Zepbound notched sales of $4.9 billion in its first full year on the market.
For 2025, the Indianapolis drugmaker expects adjusted earnings to range between $22.50 and $24 with revenue falling between $58 billion and $61 billion.
.jpeg)
